These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22023676)

  • 1. Variable selection for qualitative interactions in personalized medicine while controlling the family-wise error rate.
    Gunter L; Zhu J; Murphy S
    J Biopharm Stat; 2011 Nov; 21(6):1063-78. PubMed ID: 22023676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing a randomized clinical trial to evaluate personalized medicine: a new approach based on risk prediction.
    Baker SG; Sargent DJ
    J Natl Cancer Inst; 2010 Dec; 102(23):1756-9. PubMed ID: 21044964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LIBERTI: A SMART study in plastic surgery.
    Hibbard JC; Friedstat JS; Thomas SM; Edkins RE; Hultman CS; Kosorok MR
    Clin Trials; 2018 Jun; 15(3):286-293. PubMed ID: 29577741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simulation study on estimating biomarker-treatment interaction effects in randomized trials with prognostic variables.
    Haller B; Ulm K
    Trials; 2018 Feb; 19(1):128. PubMed ID: 29463271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detecting treatment-covariate interactions using permutation methods.
    Wang R; Schoenfeld DA; Hoeppner B; Evins AE
    Stat Med; 2015 May; 34(12):2035-47. PubMed ID: 25736915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Introduction: Personalized medicine: what is it and what are the challenges?
    Sigman M
    Fertil Steril; 2018 Jun; 109(6):944-945. PubMed ID: 29935651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy.
    Laber EB; Zhao YQ; Regh T; Davidian M; Tsiatis A; Stanford JB; Zeng D; Song R; Kosorok MR
    Stat Med; 2016 Apr; 35(8):1245-56. PubMed ID: 26506890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized medicine in Europe: not yet personal enough?
    Di Paolo A; Sarkozy F; Ryll B; Siebert U
    BMC Health Serv Res; 2017 Apr; 17(1):289. PubMed ID: 28424057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlling the family-wise error rate in multi-arm, multi-stage trials.
    Crouch LA; Dodd LE; Proschan MA
    Clin Trials; 2017 Jun; 14(3):237-245. PubMed ID: 28545335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On Enrichment Strategies for Biomarker Stratified Clinical Trials.
    Wang X; Zhou J; Wang T; George SL
    J Biopharm Stat; 2018; 28(2):292-308. PubMed ID: 28933670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
    Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G
    Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized Reference Intervals in Laboratory Medicine: A New Model Based on Within-Subject Biological Variation.
    Coşkun A; Sandberg S; Unsal I; Cavusoglu C; Serteser M; Kilercik M; Aarsand AK
    Clin Chem; 2021 Jan; 67(2):374-384. PubMed ID: 33188412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of methods for detecting interacting loci.
    Chen L; Yu G; Langefeld CD; Miller DJ; Guy RT; Raghuram J; Yuan X; Herrington DM; Wang Y
    BMC Genomics; 2011 Jul; 12():344. PubMed ID: 21729295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond.
    Ginsburg GS; Kuderer NM
    J Clin Oncol; 2012 Dec; 30(34):4233-42. PubMed ID: 23071236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variable Selection for Qualitative Interactions.
    Gunter L; Zhu J; Murphy SA
    Stat Methodol; 2011 Jan; 1(8):42-55. PubMed ID: 21179592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying predictive markers for personalized treatment selection.
    Shen Y; Cai T
    Biometrics; 2016 Dec; 72(4):1017-1025. PubMed ID: 26999054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Personalized Cardiovascular Medicine Today: A Food and Drug Administration/Center for Drug Evaluation and Research Perspective.
    Blaus A; Madabushi R; Pacanowski M; Rose M; Schuck RN; Stockbridge N; Temple R; Unger EF
    Circulation; 2015 Oct; 132(15):1425-32. PubMed ID: 26459078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current strategies to streamline pharmacotherapy for older adults.
    Schlender JF; Vozmediano V; Golden AG; Rodriguez M; Samant TS; Lagishetty CV; Eissing T; Schmidt S
    Eur J Pharm Sci; 2018 Jan; 111():432-442. PubMed ID: 29032303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized ovarian stimulation for assisted reproductive technology: study design considerations to move from hype to added value for patients.
    Mol BW; Bossuyt PM; Sunkara SK; Garcia Velasco JA; Venetis C; Sakkas D; Lundin K; Simón C; Taylor HS; Wan R; Longobardi S; Cottell E; D'Hooghe T
    Fertil Steril; 2018 Jun; 109(6):968-979. PubMed ID: 29935655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.